Form 4: Insmed Inc. Director Clarissa Desjardins Reports Stock Purchases

Director Clarissa Desjardins reports purchasing Insmed Inc. (INSM) stock in two transactions on May 20 and May 21, 2025.

Summary

• Clarissa Desjardins, a director of Insmed Inc. (INSM), filed a Form 4 indicating changes in beneficial ownership.
• On May 20, 2025, she purchased 1,895 shares of common stock at a weighted average price of $66.87 per share.
• These shares were purchased at prices ranging from $66.75 to $66.98 per share.
• On May 21, 2025, she purchased an additional 1,130 shares at $66.35 per share.
• Following these transactions, Ms. Desjardins directly owns 67,007 shares and indirectly owns 3,025 shares through her spouse.

Sentiment

Score: 7

Explanation: Director's stock purchase generally indicates positive sentiment, suggesting confidence in the company's future performance. However, the scale of the purchase is relatively small.

Positives

• The director's purchase of shares may signal confidence in the company's future prospects.

Industry Context

Director's stock purchases are often viewed as a positive sign, indicating confidence in the company's performance and future prospects within the biotechnology industry.

Comparison to Industry Standards

• Comparing insider trading activity at Insmed to similar biotech companies like Vertex Pharmaceuticals (VRTX) or Amgen (AMGN) can provide context.
• For example, if other biotech firms see similar insider buying patterns, it could reflect broader industry optimism.
• Conversely, a lack of insider buying at comparable companies might make Insmed's activity stand out.

Stakeholder Impact

• The director's stock purchase could positively influence shareholder sentiment.
• It may also boost employee morale by signaling confidence in the company's direction.

Key Dates

Keywords

Insmed, INSM, Form 4, Beneficial Ownership, Director, Stock Purchase, Clarissa Desjardins